IMP4297 Capsule (JS109)

IMP4297 · Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IMP4297 Capsule (JS109), covering 2024-09-05 to 2024-09-05. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors [Phase 1, Phase 2]

See pricing